Data show sustained benefits of deucrictibant for HAE attacks - Angioedema News
Deucrictibant effectively prevents and treats hereditary angioedema (HAE) attacks in clinical trials, with sustained reductions in attack rates and faster symptom relief. Pharvaris is advancing Phase 3 trials for both prophylactic and on-demand treatment formulations.
Related Clinical Trials
Reference News
Pharvaris plans to initiate a Phase 3 trial, CHAPTER-3, by year-end to test an oral, extended-release tablet of deucrictibant for hereditary angioedema (HAE). The trial aims to assess safety and efficacy in reducing HAE attacks. Pharvaris also intends to pursue deucrictibant's development for acquired angioedema, following promising data from an Amsterdam study. Deucrictibant, designed to block the bradykinin B2 receptor, is available in both extended-release and immediate-release formulations.
Deucrictibant effectively prevents and treats hereditary angioedema (HAE) attacks in clinical trials, with sustained reductions in attack rates and faster symptom relief. Pharvaris is advancing Phase 3 trials for both prophylactic and on-demand treatment formulations.